A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Adrenergic Agonists; Solabegron

Criteria

Inclusion Criteria:

• Diagnosis of IBS which meets the Rome II criteria, screening pain score to be > 1.5 (0= no pain, 4 = very severe pain)

Exclusion Criteria:

• Subjects not meeting the Rome II criteria for the diagnosis of IBS

• Subjects with no stool for 7 days during the screen